Clinical trials: Malaria Fever
Malaria
Examine Safety and Immune Responses of GSK 257049 Vaccine When Administered to Infants Living in a Malaria-endemic Region
GSK Biologicals is developing in partnership with the Program for Appropriate Technology in Health (PATH) Malaria Vaccine Initiative a candidate malaria vaccine for the routine immunization of infants and children living in…
- Trial name
- NCT00197028
- Testing
- RTS,S/AS02D, TETRActHib™, Engerix-B®
- Where
- Mozambique
- Volunteers
- 214 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria
Long-Term Follow-up of Children for a 2-Year Period to Confirm the Safety and Immunogenicity of GSK 257049 Vaccine
The RTS,S/AS02A vaccine (or GSK 257049 vaccine), GSK Biologicals' candidate Plasmodium falciparum (P. falciparum) malaria vaccine is being developed for the routine immunization of infants and children living in malaria endemic…
- Trial name
- NCT00323622
- Testing
- GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049, Engerix™-B, Hiberix®
- Where
- Mozambique
- Volunteers
- 1,737 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria,Falciparum, Child, Only
Seasonal Malaria Vaccination (RTS,S/AS01) and Seasonal Malaria Chemoprevention (SP/AQ) Extension Study
A double-blind, individual randomised trial will be undertaken in children under five years of age living in areas of Burkina Faso or Mali where the transmission of malaria is intense and highly seasonal to determine whether…
- Trial name
- RTSS-SMC (NCT04319380)
- Testing
- Tetanus/diphtheria toxoids, SMC with SP+AQ, RTS,S/AS01
- Where
- 2 sites in Burkina Faso, Mali
- Volunteers
- 5,098 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Malaria
Safety and Efficacy Study of IV Artesunate to Treat Malaria
The purpose of this study is to determine how GMP IV Artesunate is metabolized and cleared by individuals with uncomplicated malaria infection and to determine how fast it eliminates malaria infection from the body.
- Trial name
- NCT00298610
- Testing
- Artesunate, Malarone
- Where
- Kenya
- Volunteers
- 30 people
- Sponsor
- U.S. Army Medical Research and Development Command
Malaria, Falciparum, Malaria, Vivax
Efficacy of SJ733 in Adults With Uncomplicated Plasmodium Falciparum or Vivax Malaria
This Phase 2a trial recruits adult patients with uncomplicated P. vivax or P. falciparum blood-stage malaria mono-infection. The study drug SJ733 will be administered to examine its antimalarial efficacy, safety, and…
- Trial name
- NCT04709692
- Testing
- (+)-SJ000557733 (SJ733)
- Where
- Peru
- Volunteers
- 22 people
- Sponsor
- R. Kiplin Guy
Malaria, Severe Malaria
Evaluation of Oral Activated Charcoal on Antimalarial Drug's Ability to Kill Parasites in Malian Children With Malaria
Background: Malaria is caused by small parasites carried by some mosquitoes. People can get malaria if an infected mosquito bites them. Malaria destroys red blood cells.
- Trial name
- NCT01955382
- Testing
- Actidose Aqua, Artesunate, Amodiaquine
- Where
- Mali
- Volunteers
- 70 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy
Chemoprophylactic Activity of M5717 in PfSPZ Challenge Model
The main purpose of this study was to assess the chemoprophylactic activity and dose-exposure-response relationship of single oral dose of M5717 administered after direct intravenous inoculation (DVI) of Plasmodium falciparum…
- Trial name
- NCT04250363
- Testing
- PfSPZ Challenge, Palcebo, M5717 30 mg
- Where
- Netherlands
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Uncomplicated Plasmodium Falciparum Malaria
Pyronaridine and Artesunate (3:1) in Children With Acute Uncomplicated Plasmodium Falciparum Malaria
The purpose of this study is to evaluate three dose levels of a combination tablet and a fixed dose granule formulation of pyronaridine and artesunate (PA) for the treatment of acute uncomplicated falciparum malaria in children.
- Trial name
- NCT00331136
- Testing
- Pyronaridine-Artesunate
- Where
- Gabon
- Volunteers
- 60 people
- Sponsor
- Medicines for Malaria Venture
Malaria
OZ439 PhIIa Study in Plasmodium Falciparum: Extended Observation
This study aims to investigate the concentration dependent effects of OZ439 on the clearance of P. falciparum parasites in patients, specifically the determination of an in-vivo minimum inhibitory concentration (MIC) of OZ439.
- Trial name
- NCT01713621
- Testing
- OZ439
- Where
- 3 sites in Thailand
- Volunteers
- 25 people
- Sponsor
- Medicines for Malaria Venture
Malaria
Studies of a Candidate Aminoquinoline Antimalarial (AQ-13)
This is an initial efficacy study of a candidate antimalarial in human subjects with uncomplicated malaria caused by the most common and most important parasite in Africa (Plasmodium falciparum).
- Trial name
- NCT01614964
- Testing
- AQ-13 Treatment, Coartem Treatment
- Where
- Mali
- Volunteers
- 66 people
- Sponsor
- Tulane University
Malaria, Falciparum Malaria
TES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014
An antimalarial drug efficacy trial was conducted for artemether-lumefantrine (AL) and chloroquine (CQ) in the three (3) municipalities (Bataraza, Brookes and Rizal) of Palawan.
- Conditions
- Malaria, Falciparum Malaria, Vivax Malaria, Malaria Recrudescence
- Trial name
- TES (NCT04222088)
- Testing
- Arthemeter-lumefantrine, Chloroquine, Primaquine
- Volunteers
- 159 people
- Sponsor
- Research Institute for Tropical Medicine, Philippines
Malaria,Falciparum
Safety, Tolerability, and Pharmacokinetics and Pharmacodynamics of TB31F
This phase 1 study aims to assess the safety and tolerability of monoclonal antibody TB31F administered intravenously or subcutaneously at escalating dose levels in healthy, malaria naïve, adults.
- Trial name
- TB31F (NCT04238689)
- Testing
- TB31F
- Where
- Netherlands
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Plasmodium Falciparum Malaria
Superiority of ArTiMist Versus Quinine in Children With Severe Malaria
The purpose of this study is to demonstrate that ArTiMist (sublingual artemether spray) is better than intravenous quinine in reducing parasite counts by >= 90% within 24 hours after the start of treatment in children with severe…
- Trial name
- NCT01258049
- Testing
- Artemether Sublingual Spray, Quinine
- Where
- 3 sites in Burkina Faso, Ghana and 1 more
- Volunteers
- 151 people
- Sponsor
- Proto Pharma Ltd
Plasmodium Falciparum Infection, Malaria
Anti-malaria MAb in Kenyan Children
The purpose of this study is to evaluate the safety and tolerability of one-time subcutaneous (SC) administration of monoclonal antibody (MAb) L9LS in healthy Kenyan children aged 5 months to 10 years, as well as the protective…
- Trial name
- NCT05400655
- Testing
- L9LS
- Where
- Kenya
- Volunteers
- 912 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Dose Escalation PfSPZ-CVac
Background: People get malaria from bites from infected mosquitos. Researchers are studying a vaccine strategy. They will give people malaria parasites by injecting them with live infectious malaria parasites with antimalarial…
- Trial name
- NCT03083847
- Testing
- Chloroquine Phosphate, Pyrimethamine, Sanaria PfSPZ Challenge
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Safety, Tolerability & Pharmacokinetics (PK) of Co-administered Single Doses of OZ439 and Mefloquine (MQ) in Healthy Volunteers
OZ439 is a novel, synthetic trioxolane medicine which is related to artemisinin, but has the advantage of a longer elimination half-life so is being developed to be administered together with a potential partner drug e.g.
- Trial name
- NCT01615822
- Testing
- OZ439 100mg, OZ439 400mg, MQ 250 mg, single dose
- Where
- South Africa
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Plasmodium Falciparum
Safety, Immunogenicity of RTS,S/AS02A, and RTS,S/AS01B Malaria Vaccines in Malaria-experienced Adults.
The candidate malaria vaccine RTS,S/AS02A developed by GSK Biologicals demonstrated 30% efficacy against clinical episodes of malaria and approximately 58% efficacy against severe malaria disease.
- Trial name
- NCT00197054
- Testing
- RTS, S/AS01B, RTS, S/AS02A, Rabipur (Rabies) Vaccine
- Where
- Kenya
- Volunteers
- 255 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Malaria, Vivax, G6PD Deficiency
Assessing a Risk Model for G6PD Deficiency
A clinical study designed to develop and inform an individual risk of hemolysis model based on individual red blood cell G6PD levels.
- Trial name
- NCT03337152
- Testing
- primaquine, chloroquine + primaquine
- Where
- Thailand
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- PATH
Malaria, Vivax
Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in Subjects With Plasmodium Vivax Malaria
This is a prospective, double-blind, double-dummy, multicenter, comparative study. A total of 300 subjects will be randomized to treatment on Day 1, of which a minimum of 50 female subjects must be enrolled that display moderate…
- Trial name
- NCT02216123
- Testing
- Tafenoquine, Chloroquine, Primaquine
- Where
- 10 sites in Brazil, Colombia and 4 more
- Volunteers
- 251 people
- Sponsor
- GlaxoSmithKline
Malaria
Artemisinin-Based Combination Therapy: Clinical Trials in Cameroon
This proposal aims to evaluate the safety and efficacy of artemisinin-based anti-malaria combination drugs (ACTs) for the treatment of children aged 6-120 months in different locations in Cameroon.
- Trial name
- NCT00297882
- Testing
- 1. Artemether-Lumefantrine (AL), 2. Amodiaquine-Artesunate (AQ-AS)
- Volunteers
- 816 people
- Sponsor
- London School of Hygiene and Tropical Medicine